Societal costs for irritable bowel syndrome – a population based study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Irritable bowel syndrome (IBS) is associated with increased use of health care services. This study aims to estimate the costs of IBS in relation to differing diagnostic criteria of IBS, duration of symptoms, gender, and age. MATERIAL AND METHODS: A two-phase postal survey. Questionnaire I covering gastrointestinal (GI) symptoms by Manning and Rome II criteria was mailed to 5000 randomly selected adults. Questionnaire II, mailed to those fulfilling IBS criteria of Questionnaire I, recorded data on physician visits, medications, and diagnostic procedures performed. RESULTS: Proportion of GI consulters was 48% (95% CI 41-55%) and 32% (95% CI 28-36%) for Rome II and Manning groups. Annual GI related individual costs were euro 497 (95% CI euro 382-621) and euro 295 (95% CI euro 246-347) by Rome II and Manning criteria. Societal GI costs were euro 82 million and euro 154 million by Rome II and Manning criteria. Direct non-GI costs amounted to euro 43 million and euro 126 million by Rome II and Manning criteria. Duration of GI symptoms, gender, or age had no impact on GI costs. CONCLUSIONS: IBS incurs substantial GI and non-GI costs corresponding to a share of up to 5% of the national direct outpatient and medicine expenditures. The more restrictive Rome II criteria identify an IBS population incurring higher GI related individual costs than Manning criteria. Costs due to GI endoscopies are not lower for those with a long history of symptoms suggesting that guideline recommendations for avoiding repeated diagnostic procedures may not be followed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198 · cited 5×
“2 times more non-GI visits compared to controls [9].”
BackgroundResultInfluentialWhitehead, W. E., Palsson, O., & Jones, K. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32392 · Cited by 1,116 · cited 1×
“A substantial non-GI comorbidity is associated with the disorder [38].”
BackgroundMedical costs in community subjects with irritable bowel syndrome
Talley, N. J., Gabriel, S. E., Harmsen, W. S., Zinsmeister, A. R., & Evans, R. W. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90738-6 · Cited by 460 · cited 4×
“The costs of primary and secondary care visits for both GI and non-GI reasons are higher for IBS patients than patients without IBS [6], or population controls [7,8].”
BackgroundInfluentialPredictors of health care seeking for irritable bowel syndrome: a population based study
Talley, N. J., Boyce, P. M., & Jones, M. (1997) · Gut · doi:10.1136/gut.41.3.394 · Cited by 250
Mearin, X. B. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520152584770 · Cited by 240
The economic impact of irritable bowel syndrome
Inadomi, J. M., Fennerty, M. B., & Bjorkman, D. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.t01-1-01736.x · Cited by 190 · cited 2×
“In previous studies, the proportion of inpatient care varies between 7% and 70% of the direct costs in IBS [29].”
Background
Cited by
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., & Simrén, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.054 · Cited by 606
The microbiome: stress, health and disease
Moloney, R. D., Desbonnet, L., Clarke, G., Dinan, T. G., & Cryan, J. F. (2014) · Mammalian Genome · doi:10.1007/s00335-013-9488-5 · Cited by 430
“Patients with this disorder experience impaired quality of life, and with consequent increases in work absenteeism and greater demands on health care services, IBS incurs significant costs to society (Hillila et al. 2010).”
BackgroundEijsbouts, C., Zheng, T., Kennedy, N. A., Bonfiglio, F., Anderson, C. A., Moutsianas, L., Holliday, J., Shi, J., Shringarpure, S., 23andMe Research Team, et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00950-8 · Cited by 280
Economic burden of irritable bowel syndrome in China
Zhang, F., Xiang, W., Li, C.-Y., & Li, S.-C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i47.10450 · Cited by 94
Metadata
- Authors
- Hillilä, M. T., Färkkilä, N. J., & Färkkilä, M. A.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2010-02-18
- Volume
- 45
- Issue
- 5
- Pages
- 582-591
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2149553261
- Cited by
- 58
- References
- 6
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Societal costs for irritable bowel syndrome – a population based study. https://app.cochat.ai/papers/10.3109/00365521003637211
- The paper
- Hillilä, M. T., Färkkilä, N. J., & Färkkilä, M. A. (2010). Societal costs for irritable bowel syndrome – a population based study. Scandinavian Journal of Gastroenterology. https://doi.org/10.3109/00365521003637211
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.